

World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 7; 30(9): 994-1260



EDITORIAL

- 994 Role of exosomal circular RNAs as microRNA sponges and potential targeting for suppressing hepatocellular carcinoma growth and progression
Papadopoulos N, Trifylli EM
- 999 Role of albumin-bilirubin score in non-malignant liver disease
Xu SX, Yang F, Ge N, Guo JT, Sun SY
- 1005 Early prediction and prevention of infected pancreatic necrosis
Lv C, Zhang ZX, Ke L
- 1011 Impact of microplastics and nanoplastics on liver health: Current understanding and future research directions
Chiang CC, Yeh H, Shiu RF, Chin WC, Yen TH

GUIDELINES

- 1018 National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Dar FS, Abbas Z, Ahmed I, Atique M, Aujla UI, Azeemuddin M, Aziz Z, Bhatti ABH, Bangash TA, Butt AS, Butt OT, Dogar AW, Farooqi JI, Hanif F, Haider J, Haider S, Hassan SM, Jabbar AA, Khan AN, Khan MS, Khan MY, Latif A, Luck NH, Malik AK, Rashid K, Rashid S, Salih M, Saeed A, Salamat A, Tayyab GUN, Yusuf A, Zia HH, Naveed A

REVIEW

- 1043 Diseases of bile duct in children
Eiamkulbutr S, Tubjareon C, Sanpavat A, Phewplung T, Srisan N, Sintusek P
- 1073 From liver to hormones: The endocrine consequences of cirrhosis
Quiroz-Aldave JE, Gamarra-Osorio ER, Durand-Vásquez MDC, Rafael-Robles LDP, Gonzáles-Yovera JG, Quispe-Flores MA, Concepción-Urteaga LA, Román-González A, Paz-Ibarra J, Concepción-Zavaleta MJ

MINIREVIEWS

- 1096 Prediction, prevention and management of gastroesophageal reflux after per-oral endoscopic myotomy: An update
Nabi Z, Inavolu P, Duvvuru NR

ORIGINAL ARTICLE

Clinical Trials Study

- 1108 Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China
Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN

- 1121** Detachable string magnetically controlled capsule endoscopy for the noninvasive diagnosis of esophageal diseases: A prospective, blind clinical study

Yang YL, Qin HW, Chen ZY, Fan HN, Yu Y, Da W, Zhu JS, Zhang J

- 1132** Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?

Gravina AG, Panarese I, Trotta MC, D'Amico M, Pellegrino R, Ferraraccio F, Galdiero M, Alfano R, Grieco P, Federico A

Observational Study

- 1143** Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors

Wang SS, Ji MY, Huang X, Li YX, Yu SJ, Zhao Y, Shen L

- 1154** Recent trends in the epidemiology and clinical outcomes of inflammatory bowel disease in South Korea, 2010-2018

Kim S, Lee HJ, Lee SW, Park S, Koh SJ, Im JP, Kim BG, Han KD, Kim JS

Prospective Study

- 1164** Staging liver fibrosis with various diffusion-weighted magnetic resonance imaging models

Jiang YL, Li J, Zhang PF, Fan FX, Zou J, Yang P, Wang PF, Wang SY, Zhang J

- 1177** sTREM-1 as promising prognostic biomarker for acute-on-chronic liver failure and mortality in patients with acute decompensation of cirrhosis

Yu SM, Li H, Deng GH, Wang XB, Zheng X, Chen JJ, Meng ZJ, Zheng YB, Gao YH, Qian ZP, Liu F, Lu XB, Shi Y, Shang J, Chen RC, Huang Y

Basic Study

- 1189** Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury

Jiang JL, Zhou YY, Zhong WW, Luo LY, Liu SY, Xie XY, Mu MY, Jiang ZG, Xue Y, Zhang J, He YH

SYSTEMATIC REVIEWS

- 1213** Treatment of *Helicobacter pylori* with potassium competitive acid blockers: A systematic review and meta-analysis

Kanu JE, Soldera J

SCIENTOMETRICS

- 1224** Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis

Li HY, Zheng LL, Hu N, Wang ZH, Tao CC, Wang YR, Liu Y, Aizimuaji Z, Wang HW, Zheng RQ, Xiao T, Rong WQ

CASE REPORT

- 1237** PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report

Kong YH, Xu ML, Zhang JJ, Chen GQ, Hong ZH, Zhang H, Dai XX, Ma YF, Zhao XR, Zhang CY, Chen RZ, Xing PF, Zhang LY

LETTER TO THE EDITOR

- 1250** Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective
Huang JG
- 1253** Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis
Colapietro F, Pugliese N, Voza A, Aghemo A, De Nicola S
- 1257** Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future indication expansion
Zhu YN, Yuan XL, Liu W, Zhang YH, Mou Y, Hu B, Ye LS

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Pal Miheller, MD, PhD, Assistant Professor, Department of Surgery, Transplantation and Gastroenterology, Head of Gastroenterology, Semmelweis University, Budapest H-1088, Pest, Hungary. miheller.pal@semmelweis.hu

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 7, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective

James Guoxian Huang

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Nikolić M, Croatia

Received: November 11, 2023

Peer-review started: November 11, 2023

First decision: January 5, 2024

Revised: January 8, 2024

Accepted: February 5, 2024

Article in press: February 5, 2024

Published online: March 7, 2024



James Guoxian Huang, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore 119228, Singapore

James Guoxian Huang, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

Corresponding author: James Guoxian Huang, MBBS, MRCP, Assistant Professor, Doctor, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Khoo Teck Puat-National University Children's Medical Institute, National University Health System, NUHS Tower Block Level 12, 1E Kent Ridge Road, Singapore 119228, Singapore.

paehgj@nus.edu.sg

Abstract

The utilisation of polygenic scoring models may enhance the clinician's ability to risk stratify an inflammatory bowel disease patient's individual risk for venous thromboembolism (VTE) and guide the appropriate usage of VTE thromboprophylaxis, yet there is a need to validate such models in ethnically diverse populations.

Key Words: Thromboembolism; Inflammatory bowel disease; Genetic screening; Venous thromboembolism; Thromboprophylaxis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Polygenic scoring models may determine an inflammatory bowel disease patient's actual risk for venous thromboembolism (VTE) with greater accuracy than monogenic screening alone. This may be due to the cumulative effect of multiple pro-thrombotic genetic loci having a greater influence on thrombotic risk, rather than specific genetic mutations. There needs to be cross-validation of such scoring models in ethnically diverse populations as there is significant heterogeneity in the prevalence of genes implicated in thrombophilia. A composite score combining clinical and polygenic risk factors would further enhance the accuracy in determining one's VTE risk.

Citation: Huang JG. Genetic risk stratification of inflammatory bowel disease-associated venous thromboembolism: An Asian perspective. *World J Gastroenterol* 2024; 30(9): 1250-1252

URL: <https://www.wjgnet.com/1007-9327/full/v30/i9/1250.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i9.1250>

TO THE EDITOR

I read with interest a cohort study recently published by Rifkin *et al*[1] on the utility of genetic scoring models in the risk stratification for venous thromboembolism (VTE) in inflammatory bowel disease (IBD) patients. The premise of the study is similar to an earlier publication by Naito *et al*[2], in which the latter demonstrates the added value of polygenic genotyping to monogenic sequencing alone in determining VTE risk in a fairly large cohort of 792 IBD patients.

This current study, however, utilises genotyping scoring data from a much larger cohort of VTE cases and validates its scoring model in a large IBD cohort ($n = 8300$) extracted from a biobank. The authors had intentionally analysed a modified polygenic scoring model (PGS) that excluded the genetic contributions of the two mutations (F5: Factor V Leiden, F2: G20210A prothrombin gene mutation). Hence, they were able to demonstrate the clear superiority of polygenic risk scoring to monogenic risk screening in discriminating actual risk of VTE. Patients at the lowest decile of PGS had a far lower incidence of VTE (1.58%) than non-mutation carriers (4.31%). Interestingly, there was only a modest increment in discriminatory ability once the monogenic mutations of F5/F2 were re-added back into the PGS model.

The data suggests that an individual's genetic risk for VTE may be influenced to a greater extent by the cumulative effects of multiple pro-thrombotic genetic loci, rather than specific mutations alone. A multitude of clinical factors, such as ethnicity, comorbidities, IBD extent and activity, hypoproteinemic state, physical immobility, steroid use *etc.*, further add to the complexity in determining one's VTE risk in IBD. I agree with the authors' statement that additional data for non-European IBD patients is urgently needed, as previous publications do show commonly screened genetic mutations such as F5/F2 have a far smaller contributory role to VTE risk in other ethnic populations *e.g.* Asians and Africans[3-6]. This may also have implications in the standard diagnostic workup for thrombophilia in the non-European patient- it is possible a polygenic screening strategy may be more informative than monogenic testing. The authors also acknowledge that they did not analyse for other common mutations in anti-thrombin III protein (SERPINC1), protein C (PROC) and protein S (PROS1) given the relative rarity of such mutations. I would like to highlight that these mutations are relatively common in the Asian population compared to F5/F2 mutations, with a recent meta-analysis by Zhu *et al*[7] demonstrating the prevalence of PROC, PROS1 and SERPINC1 deficiency at 7.1%, 8.3% and 3.8% respectively in East Asian patients with VTE. This reiterates the need to validate the PGS model in other ethnic populations, as well as its performance against regionally prevalent thrombophilia mutations.

Precision medicine and personalised therapy remain as lofty targets at least in the current realm of IBD care, but the utilisation of a personalised, regionally validated risk scoring model would provide IBD clinicians invaluable guidance and confidence in the initiation of pharmacological thromboprophylaxis. Current adherence rates to thromboprophylaxis in hospitalised IBD patients remain low in spite of existing guidelines and the potential morbidity from IBD-associated VTE[8]. A composite score combining clinical and polygenic risk factors for VTE can identify the IBD patient at highest risk, justifying the continued use of thromboprophylaxis beyond hospitalisation for instance[9]. An objective assessment of VTE risk would also personalise therapeutic decisions pertaining to IBD control itself, with a greater impetus to consciously utilise steroid-sparing strategies in high-risk patients[10].

FOOTNOTES

Author contributions: Huang JG wrote the letter; and Huang JG revised the letter.

Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Singapore

ORCID number: James Guoxian Huang 0000-0002-5869-4194.

S-Editor: Qu XL

L-Editor: A

P-Editor: Qu XL

REFERENCES

- 1 Rifkin AS, Shi Z, Wei J, Zheng SL, Helfand BT, Cordova JS, Biank VF, Tafur AJ, Khan O, Xu J. Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort. *World J Gastroenterol* 2023; **29**: 5494-5502 [PMID: [37900992](#) DOI: [10.3748/wjg.v29.i39.5494](#)]
- 2 Naito T, Botwin GJ, Haritunians T, Li D, Yang S, Khrom M, Braun J; NIDDK IBD Genetics Consortium, Abbou L, Mengesha E, Stevens C, Masamune A, Daly M, McGovern DPB. Prevalence and Effect of Genetic Risk of Thromboembolic Disease in Inflammatory Bowel Disease. *Gastroenterology* 2021; **160**: 771-780.e4 [PMID: [33098885](#) DOI: [10.1053/j.gastro.2020.10.019](#)]
- 3 De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. *Semin Thromb Hemost* 1998; **24**: 367-379 [PMID: [9763354](#) DOI: [10.1055/s-2007-996025](#)]
- 4 Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. *Am J Med Genet* 1997; **73**: 334-336 [PMID: [9415695](#) DOI: [10.1002/\(sici\)1096-8628\(19971219\)73:3<334::aid-ajmg20>3.0.co;2-j](#)]
- 5 Biswas A, Bajaj J, Ranjan R, Meena A, Akhter MS, Yadav BK, Sharma V, Saxena R. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis? *Clin Chim Acta* 2008; **392**: 21-24 [PMID: [18342013](#) DOI: [10.1016/j.cca.2008.02.018](#)]
- 6 Qi X, Wu F, Ren W, He C, Yin Z, Niu J, Bai M, Yang Z, Wu K, Fan D, Han G. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. *Thromb Haemost* 2013; **109**: 878-884 [PMID: [23447059](#) DOI: [10.1160/TH12-10-0784](#)]
- 7 Zhu XJ, Liu ZY, Wang PW, Wang J, Wen SD, Zhang JX, Zhu YJ, Sun ML, Xu XQ, Sun K, Lian TY, Cheng CY, Jing ZC. Congenital thrombophilia in East-Asian venous thromboembolism population: a systematic review and meta-analysis. *Res Pract Thromb Haemost* 2023; **7**: 102157 [PMID: [37674867](#) DOI: [10.1016/j.rpth.2023.102157](#)]
- 8 Levartovsky A, Barash Y, Ben-Horin S, Ungar B, Klang E, Soffer S, Kopylov U. Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease-Are We There Yet? *J Clin Med* 2020; **9** [PMID: [32858826](#) DOI: [10.3390/jcm9092753](#)]
- 9 Faye AS, Wen T, Ananthakrishnan AN, Lichtiger S, Kaplan GG, Friedman AM, Lawlor G, Wright JD, Attenello FJ, Mack WJ, Lebowitz B. Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2020; **18**: 1133-1141.e3 [PMID: [31336196](#) DOI: [10.1016/j.cgh.2019.07.028](#)]
- 10 Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 857-873 [PMID: [34453143](#) DOI: [10.1038/s41575-021-00492-8](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

